Imbio PHA (4.0.0) vs VitalRhythm
AI Verdict
Choose Imbio PHA (4.0.0) if…
Choose Imbio PHA if your primary need is to rapidly and automatically assess cardiac structural changes, specifically right ventricular dilation and pulmonary artery dimensions, from existing CT pulmonary angiogram (CTPA) scans. This tool is ideal for aiding in the diagnosis and risk stratification of conditions like pulmonary embolism and hypertension by providing quantitative measurements and ratios from medical images.
View Imbio PHA (4.0.0) →Choose VitalRhythm if…
Choose VitalRhythm if you require continuous, long-term remote monitoring for cardiac arrhythmias in patients outside of an acute care setting. This AI-powered cloud-based software, integrated with the VitalPatch biosensor, is best suited for detecting and analyzing a wide range of arrhythmias to support non-urgent clinical decision-making and ongoing patient management.
View VitalRhythm →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Imbio PHA (4.0.0) | VitalRhythm |
|---|---|---|
| Deployment | Cloud (AWS) or On-premise (VMware) or via partners (Nuance, Aidoc, Siemens Syngo.via, TeraRecon, FerrumHealth, Flywheel). | Cloud-based |
| FDA Status | Yes AI-estimated | Cleared AI-estimated |
| HIPAA | Yes AI-estimated | Unknown |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
Imbio PHA (4.0.0)Imbio PHA integrates directly into native DICOM tools and workflows, which is crucial for seamless adoption within radiology departments and minimizes disruption to existing processes. This direct integration often leads to a more intuitive and efficient user experience for radiologists compared to a separate web application.
Clinical Value
Imbio PHA (4.0.0)Imbio PHA provides objective, automated measurements from CTPA scans that directly aid in the diagnosis and risk stratification of critical conditions like pulmonary embolism and hypertension. This offers immediate, actionable clinical insights for acute patient management. VitalRhythm provides continuous monitoring, which is valuable, but Imbio PHA's direct impact on acute diagnostic pathways gives it a slight edge in immediate clinical decision-making.
Pricing & Value
TieBoth Imbio PHA and VitalRhythm require direct contact for pricing information, offering no public transparency on costs. Without specific pricing details or publicly available return-on-investment data, it is impossible to conduct a meaningful comparison of their value propositions.
Enterprise Readiness
Imbio PHA (4.0.0)Imbio PHA offers flexible deployment options including Cloud, Enterprise (on-premise), or via partners, which caters to a broader range of IT infrastructure and security requirements in large healthcare organizations. VitalRhythm is solely cloud-based, which, while common, offers less deployment flexibility for some enterprise clients.
Innovation
VitalRhythmVitalRhythm demonstrates greater innovation by integrating a wearable biosensor with cloud-based AI for continuous, remote patient monitoring, enabling a proactive and out-of-hospital care model. This approach extends beyond traditional diagnostic workflows, offering a more transformative impact on patient management. Imbio PHA's automation of image measurements, while valuable, is an optimization of existing diagnostic processes.
Support & Docs
TieWhile both companies offer support channels, neither the provided structured facts nor a general web search yielded sufficient comparative details regarding the depth, accessibility, or quality of their support documentation to definitively pick a winner. Imbio provides user manuals for its products, and VitalConnect offers an IT Administration Guide and patient support documents, but a direct comparison of the overall support ecosystem is not possible with the available information.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Imbio PHA (4.0.0) | VitalRhythm |
|---|---|---|
| Product Name | Imbio PHA (4.0.0) | VitalRhythm |
| Company | Imbio | VitalConnect |
| Primary Use Case | Measures cardiac structures from CTPA scans to assess potential right ventricular dilation and aid in the diagnosis and risk stratification of pulmonary embolism and hypertension. | Continuous cardiac arrhythmia detection and analysis, integrating with a biosensor for remote patient monitoring. |
| Target Specialties | Cardiology, Pulmonology, Radiology | Cardiology, Hospital Medicine, Internal Medicine |
| Core AI Function | Automated measurement of right and left ventricle diameters, main pulmonary artery and aorta diameters; calculates RV/LV and PA/Ao ratios. | Continuous ECG signal analysis; detects various cardiac arrhythmias (e.g., atrial fibrillation, AV block, supraventricular tachycardia, ventricular tachycardia, pauses). |
| Input Data Source | CT pulmonary angiogram (CTPA) scans | VitalPatch biosensor (ECG signal) |
| Output/Reporting | Annotated DICOM images, summary reports in PDF format | Displays detected arrhythmias for review by healthcare professionals via VistaCenter web application |
Videos
Demos, reviews, and walkthroughs featuring Imbio PHA (4.0.0) and VitalRhythm.